Hepatitis B Vaccines Commonly Used in India
The most commonly used hepatitis B vaccines in India are indigenous recombinant vaccines including Shanvac-B, GeneVac-B, and Engerix-B, along with combination vaccines such as pentavalent (DPT-HepB-Hib) and hexavalent formulations that incorporate hepatitis B antigen.
Indigenous Recombinant Vaccines
India has developed and widely deployed several indigenous recombinant hepatitis B vaccines that have demonstrated efficacy comparable to international formulations:
Shanvac-B is a recombinant DNA hepatitis B vaccine that has shown high efficacy in Indian healthcare workers, with seroprotection rates of 45% in males and 72% in females after the standard 0,1,6-month schedule 1. This vaccine has been extensively studied in high-risk populations including infants born to HBsAg-positive mothers 2.
GeneVac-B is another low-cost Indian recombinant vaccine that achieved 100% seroconversion and seroprotection in high-risk newborns, with geometric mean titers of 90.5 mIU/mL one month after completion of the three-dose series 2. The antibody levels increase with age, reaching 226.7 mIU/mL one year post-vaccination 2.
Engerix-B (international formulation) is also widely available in India and demonstrated comparable immunogenicity to indigenous vaccines, with GMT values of 80.9 mIU/mL and 193.9 mIU/mL at one month and one year post-vaccination respectively 2.
Combination Vaccines in Universal Immunization Program
India has strategically incorporated hepatitis B vaccination into combination vaccines to improve coverage and reduce injection burden:
Pentavalent vaccine (DPT-HepB-Hib) was introduced into India's Universal Immunization Program and protects against five diseases including hepatitis B 3. This combination vaccine automatically raises hepatitis B coverage to match DPT coverage levels, eliminating the gap that occurs when vaccines are provided individually 3.
Hexavalent vaccines containing diphtheria, tetanus, pertussis, Haemophilus influenzae type b, poliomyelitis, and hepatitis B are available in three formulations in India: DTwP-Hib/HepB-IPV, DTaP-IPV-HB-PRP~T, and DTaP-HBV-IPV/Hib 4. These vaccines are used for the primary series at 6,10, and 14 weeks of age, with seroprotection rates for hepatitis B ranging from 88.2-100% depending on the formulation 4.
Vaccination Schedule and Dosing
The standard hepatitis B vaccination schedule in India follows international guidelines:
Birth dose is administered within 24 hours of birth, particularly critical for infants born to HBsAg-positive mothers 2, 5.
Primary series consists of three doses at 0,1, and 6 months using 10 μg dosage for infants and children 2.
Coverage data from Mayurbhanj district showed that 90.9% of children received the birth dose, while 98.1%, 97.3%, and 96.1% received the three subsequent pentavalent doses 5. However, only 72.6% achieved protective antibody levels above 10 IU/mL, indicating a need for improved follow-up 5.
Clinical Considerations
Important caveats for hepatitis B vaccination in India:
Pre-vaccination screening is strongly recommended for healthcare workers due to high baseline HBV/HCV infection rates (36.2% showed at least one marker of infection in one study) 1.
Female recipients demonstrate significantly higher immunogenicity than males, with geometric mean titers of 257 vs. 29 mIU/mL in healthcare workers 1.
Smoking and alcoholism are significantly correlated with unsatisfactory vaccine response 1.
All three indigenous vaccines (Shanvac-B, GeneVac-B, Engerix-B) showed no significant differences in safety or immunogenicity, with no systemic reactions reported 2.
The prevalence of HBV infection among children aged 1-5 years in rural/tribal areas remains at 0.8%, highlighting the ongoing need for improved vaccination coverage and timely administration 5.